T1	Participants 91 167	patients with newly diagnosed, previously untreated chronic myeloid leukemia
T2	Participants 413 484	patients with newly diagnosed chronic myeloid leukemia in chronic phase
T3	Participants 91 184	patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase
T4	Participants 518 612	476 patients were randomly assigned 2:1 to imatinib 800 mg (n = 319) or 400 mg (n = 157) daily
